Solutions

One platform.Configured for how Indian trials run.

Bioequivalence, generics development, multi-therapy CRO operations, sponsor programs, and academic research — on the same data model and audit trail.

By who you are

Built for Indian CROs, end to end.

Built-in PK sampling schedules, replicate-design support, and ANDA-ready exports — for the segment where India leads global study volume.

Short, focused trials at scale — pricing and tooling aligned to how generic-drug development actually operates in India.

Phase II to IV across therapeutic areas — same data model, configurable workflows, one continuous audit trail.

Sponsor-grade quality, DPDP-aligned, and CDSCO submission support — without disrupting the global team's tooling.

Own your trial data, end to end — under DPDP Act 2023, with Indian-jurisdiction contracting.

Designed for AIIMS-equivalent, ICMR-funded, and DBT-funded research — without enterprise-CRO overhead or USD pricing.

By phase

From bioequivalence studies and first-in-human dose escalation to long-running post-marketing surveillance.

By therapy area

Oncology, cardiology, infectious disease, rare disease, and devices — configured to the protocol.